CHRS Coherus BioSciences Inc.

20.67
0  0%
Previous Close 20.67
Open
Price To Book -36.91
Market Cap 1,433,887,346
Shares 69,370,457
Volume 0
Short Ratio
Av. Daily Volume 902,006

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data released January 2016. Endpoints met. However, commercialization not possible in US before 2029 due to patent issues
CHS-0214
Rheumatoid arthritis
Phase 2b data released June 2016
CHS-131
Relapsing remitting multiple sclerosis (RRMS)
Phase 3 top-line data met endpoints August 2016. BLA filing due late 2019.
CHS-1420
Psoriasis
Phase 3 trial met endpoint November 2015. However, commercialization not possible in US before 2029 due to patent issues
CHS-0214
Psoriasis
FDA approval announced November 2, 2018.
CHS-1701
Pegfilgrastim biosimilar